Law360, New York (August 20, 2015, 10:44 AM EDT) -- This week, the U.S. Food and Drug Administration Office of Prescription Drug Promotion (OPDP) issued a warning letter to Duchesnay Inc. regarding certain Facebook, Instagram and Twitter social media posts made by Kim Kardashian about the company's product DICLEGIS, which is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. While OPDP has reduced its issuance of warning and untitled letters in the past two years,[1] this warning letter demonstrates the agency's ability to swiftly threaten enforcement action and demand broad corrective action when it has concerns about social media promotion.[2] It also demonstrates that OPDP's Bad Ad Program is still in full force, as the violative materials were submitted as a complaint....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
